《太美医疗科技&VMS：2023人工智能商业化白皮书（英文版）（10页）.pdf》由会员分享，可在线阅读，更多相关《太美医疗科技&VMS：2023人工智能商业化白皮书（英文版）（10页）.pdf（10页珍藏版）》请在三个皮匠报告上搜索。

1、The AI outlook for clinical trials:discover new capabilities and efficiencies at every stageHow the latest developments are saving sponsors time and money while improving quality and safety Artificial intelligence(AI)is expected to be the most disruptive emerging technology in the pharma sector in 2

2、023,according to GlobalData.AI spending by pharma companies is predicted to grow at a combined annual growth rate(CAGR)of 18.5%to reach USD 0.9 billion in 2024,and medical device companies are expected to spend USD 0.5 billion by 2024,a CAGR of 20.6%.AI promises to transform clinical research at alm

3、ost every stage,offering new efficiency,accuracy and more powerful analytics than ever before and equipping sponsors to handle a clinical trials market that is growing in scope,scale and competition.2IntroductionAI is transforming the way we work in almost every sector.Advanced analytics,automation

4、and speed can be brought to bear on a diverse range of applications,from security and compliance to user experience and customer service.Not only can AI make processes more efficient by increasing speed and accuracy,it can also do things that humans cant,offering brand new,more powerful capabilities

5、.Combined with advanced technologies like big data,machine learning(ML)and knowledge graphs,AI is becoming ever more valuable and even essential for the future of business.Meanwhile,the clinical trials landscape is evolving.In recent years,the industry has been impacted by significant macro trends,i

6、ncluding the COVID-19 pandemic,climate pressures and geopolitical instability,which have affected supply chains,regulatory requirements and patient populations as well as transformed the way clinical research is conducted.As todays clinical trials grow in scale and scope,they are producing more data